Editas Medicine 2024年第四季度GAAP每股亏损$0.55,不及预期$0.38,销售额$30.604M不及预期$32.230M

财报速递2025-03-06
Editas Medicine (NASDAQ:EDIT) 报告季度每股亏损$0.55,低于分析师普遍预期的$0.38,相差44.74%。与去年同期每股亏损$0.23相比,这是一个139.13%的下降。公司报告季度销售额为$30.604百万,低于分析师普遍预期的$32.230百万,相差5.04%。与去年同期的$60.050百万相比,这是一个49.04%的下降。

以上内容来自Benzinga Earnings专栏,原文如下:

Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.38) by 44.74 percent. This is a 139.13 percent decrease over losses of $(0.23) per share from the same period last year. The company reported quarterly sales of $30.604 million which missed the analyst consensus estimate of $32.230 million by 5.04 percent. This is a 49.04 percent decrease over sales of $60.050 million the same period last year.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法